1Luef G, Rauchenzauner M, Waldmann M, et al. Non-alcoholic fatty liver disease(NAFLD), insulin resistance and lipid profile in antiepi- leptic drug treatment[J]. Epilepsy Res, 2009, 86(1): 42-47.
2Gastaldelli A, Kozakova M, H jlund K, et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population[J]. Hepatology, 2009, 49(5): 1537-1544.
5Uzun MA, Koksal N, Aktas S, et al. The effect of ursodeoxycholic acid on liver regeneration after partial hepatectomy in rats with non-alcoholic fatty liver disease[J]. Hepatol Res, 2009, 39(8): 814- 821.
6Masubuchi Y.Metabolic and non-metabolic factors determining troglitazone hepatotoxicity[J].Drug Metab Pharmacokinet,2006,21(5):347
7Neuschwander-Tetri BA,Brunt EM,Wehmeier KR,et al.Improved non-alcoholic steatohepatitis after 48 weeks of treatment with the PPAR2-gamma ligand rosiglitazone[J].Hepatology,2003,10:1008
1Wong VWS,Chu WCW, Wong GLH, et al. Prevalence of non- al- coholic fatty liver disease and advanced fibrosis in Hong Kong Chi- nese: A population study using proton-magnetic resonance spectros- copy and transient elastography[ J]. Gut,2012,61 (3) :409 -415.
2Dunn W,Sanyal AJ,Brunt EM,et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitls in patients with non-alcoholic fatty liver disease (NAFLD) [ J]. J Hepatol, 2012,57(2) :384 - 391.
